+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
ID07362017

Multicenter Open Label Study Evaluating Safety and Efficacy of Ponesimod for Moderate-to-Severe Chronic Plaque Psoriasis

Led by Vanda Pharmaceuticals · Updated on 2026-09-22

300

Participants Needed

10

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of ponesimod in adults with moderate-to-severe chronic plaque psoriasis. This phase 3 open-label study focuses on participants aged 18 to 65 who have significant skin involvement as measured by body surface area and psoriasis severity scores. Participants will receive ponesimod as an oral tablet during the study. The study uses a single group design where all participants receive the investigational drug. The treatment period lasts approximately one year, during which safety and tolerability are closely monitored. During the study, participants will be regularly assessed for adverse events and psoriasis symptoms. Researchers will collect information on safety and how well participants tolerate ponesimod. The total study duration includes treatment and follow-up periods extending to about one year after starting the drug.

CONDITIONS

Brief Title

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Research Team

V

Vanda Pharmaceuticals, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here